Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared on LinkedIn:
“Our recent publication and 1st in 2026 out in Therapeutic advances in Hematology (IF 3.1)
Avatrombopag in Aplastic Anemia – Review
- Scope: 10 studies (2023–2025), diverse AA settings (frontline, R/R, elderly, liver disease)
- Efficacy: ORR 55–85%; CR up to ~30%
- Onset: Rapid responses, typically within 1–2 months
- Clinical benefit: Multilineage recovery, reduced transfusion needs
- After eltrombopag: Responses seen even in EPAG-refractory/intolerant patients
- Safety: Favorable profile; no meaningful hepatotoxicity or clonal evolution reported
- Key advantage: Suitable for patients with liver dysfunction, no dietary restrictions
Bottom line: Avatrombopag is an effective, well-tolerated TPO-RA with growing role in AA across disease stages”
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri D, Ahmed Kotb Abdrabou, Alfadil Haroon, Hadeel Samarkandi, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari
Read full article here.
Stay updated on the latest scientific advances in the field of aplastic anemia with Hemostasis Today.
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities
-
Aug 27, 2026, 10:43FDA Expands Hympavzi Approval to Children and Patients With Hemophilia A or B With Inhibitor
-
Aug 27, 2026, 10:28Narat Srivali: Exploring the Link Between Perioperative Corticosteroids and VTE Risk
-
Aug 27, 2026, 10:19Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
-
Aug 27, 2026, 07:49Denis Oduor: Bringing Blood Closer – Strengthening Kenya’s Response to PPH
-
Aug 27, 2026, 07:19Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
-
Aug 27, 2026, 06:58Priyam Bordoloi: The Biological Advantage of Two X Chromosomes